Polaryx Therapeutics, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alex Yang
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- South Tower Paramus NJ United States of America 07652
- IPO Date
- Feb 2, 2026
- CIK
- 0002075320
- Website
- polaryx.com
- Similar Companies
- Business
- Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovery, development, and commercialization of disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs) with a headquarters in Paramus, New Jersey. The company designs and advances novel therapeutic candidates, including small molecules and biologics, through preclinical and clinical development programs aimed at addressing unmet medical needs in LSDs and related neurodegenerative conditions. Polaryx operates primarily in the United States, Europe, and select Asia-Pacific sites, collaborating with research institutions, contract research organizations, and strategic partners to accelerate clinical development and regulatory progression. Main products and services - PLX-200 lead candidate: development of a disease-modifying therapy for CLN3, including Phase 3 clinical program and global study execution; formulation development and pharmacokinetic/dose optimization activities; regulatory liaison and submission support. - IND-enabled programs: preparatory work and early-phase trials for additional LSD targets (including CLN2) with strategy for expedited or accelerated pathways; preclinical pharmacology, toxicology, and CMC support for pipeline expansion. - Drug formulation and delivery platforms: patient-friendly oral solutions and buccal formulations designed to improve compliance in pediatric populations; formulation optimization, stability testing, and route-of-administration assessments. - Research collaboration and development services: partnerships with academic and industry collaborators for target validation, biomarker discovery, and translational studies; data generation to inform clinical development plans. - Regulatory and quality services: preparation of regulatory filings, interactions with health authorities, quality systems development, and manufacturing process development activities aligned with GMP standards. Latest major company changes - Nasdaq listing and ticker introduction: Polaryx secures approval to list common stock on the Nasdaq Capital Market under the ticker symbol PLYX, with trading anticipated in early February 2026, marking a material liquidity and visibility milestone for the company. - Direct listing advancement and corporate updates: the company communicates corporate updates surrounding its ongoing clinical programs, funding considerations, and strategic opportunities to accelerate development timelines and expand partnering opportunities; these updates reflect strategic pivots toward partnerships and multi-regional trial execution. - FDA interaction and first-half 2026 trial planning: following a favorable regulatory interaction (e.g., FDA “safe to proceed” letter) in late 2025, Polaryx plans to initiate pivotal and confirmatory trials across the United States, Europe, and Asia in 2026, positioning PLX-200 and related assets for broader clinical evaluation. Industry context and business segments - Industry: biotechnology and pharmaceutical development focused on rare pediatric diseases; emphasis on lysosomal storage disorders and neurodegenerative etiologies. - Segments: clinical-stage drug development; formulation and delivery technology; strategic collaborations and potential in-licensing deals; regulatory strategy and global trial execution. - Geographic footprint: primary operations in the United States (headquarters in New Jersey) with development and trial activities anticipated across North America, Europe, and Asia-Pacific regions. - Corporate relationships: operates as an independent entity with potential partnerships and collaborations; may have relationships with contract research organizations and academic institutions to advance pipeline programs. Founding year and headquarters - Founded in the 2020s (public references indicate establishment preceding 2026 activities) with headquarters at 140 East Ridgewood Avenue, Paramus, New Jersey. Subsidiaries and parent relationships - No public evidence of material subsidiary structure beyond corporate stand-alone operations; Polaryx is positioned as an independent publicly traded biotechnology company with potential future strategic partnerships and licensing arrangements. Notes - Ongoing clinical development programs, product candidates, and corporate developments are subject to regulatory changes and trial outcomes; the above reflects publicly reported items up to early 2026 and may be updated as new disclosures occur.
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
Polaryx Therapeutics (NASDAQ:PLYX) Stock Price Down 1.9% – Time to Sell?
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
What's Going On With Polaryx Therapeutics Stock Wednesday?
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Polaryx Therapeutics Welcomes New Members of the Board of Directors
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
Polaryx Therapeutics Seeks Direct Listing For Shareholders